Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The University of Oxford and University College London have come together to form CASMI - the Centre for the Advancement of Sustainable Medical Innovation.

Under the joint Chairmanship of Sir John Bell, Regius Professor of Medicine at Oxford and Sir John Tooke, UCL Vice Provost (Health) and led by founding Director, Dr Richard Barker, CASMI seeks to address one of the most important societal problems of the 21st century – turning investment in basic research into population health gain. An official launch event to mark this unique commitment by two world-leading Universities is being held at the Wellcome Trust today.

CASMI is a virtual Centre, which brings together CASMI Fellows across the partner Universities, from disciplinary areas including life and biomedical science, ethics, laws, economics, statistics, politics, business studies, psychology, sociology, behavioural science and more. This enables the Centre to bring a uniquely holistic perspective on the core problem that CASMI will tackle - turning bioscience breakthroughs into patient benefit. This challenge is also a specific area of national priority, as addressed by the Government’s Strategy for UK Life Sciences.

Dr Richard Barker, CASMI Director said: “We will deliver a unique holistic approach to tackling what’s known as the three main ‘gaps in translation’ – i) breakthroughs in the lab not producing therapies for trial; ii) too many products failing to overcome the hurdles of regulatory approval and reimbursement; and iii) approved products not being used effectively to deliver patient benefit. We will bring together the breadth of academic disciplines across UCL, Oxford and beyond to develop ‘testable models’, such as the Adaptive Licensing project already in train, supported by the Wellcome Trust.”

"Improving the productivity of medical innovation and the speed with which scientific advances are translated into new treatments is critical for the future of UK life sciences. It's our goal that CASMI plays a leading role in this arena," said CASMI Co-Chair Sir John Bell.

CASMI Co-Chair, Professor Sir John Tooke commented that “Drawing on the capacities of two world-class universities and our wider partnerships, CASMI offers the opportunity to rise to the challenge of reshaping the innovation pipeline for the benefit of both patients and the economy.”

Further details about CASMI are available on the website at www.casmi.org.uk

Similar stories

Jenner Institute named Covid Innovation Heroes

The team at the University of Oxford’s Jenner Institute has been celebrated for their global pandemic work by The Oxford Trust’s Covid Innovation Heroes Award­ 2021.

Study reveals ‘stop-eating’ response to DNA damage

A new study from the MRC Weatherall Institute of Molecular Medicine sheds light on the mechanism by which DNA damage suppresses appetite, a finding with implications for understanding the appetite lowering side-effects of chemotherapy.

World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition

Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.

Oxford-led research maps milestone stage of human development for the first time

Scientists have shed light on an important stage of early embryonic development that has never been fully mapped out in humans before.

Overusing antibiotics? Find out with Antibiotic Footprint Calculator

To help reduce the overuse of antibiotics, Oxford researchers today released a new, easy to use online tool – Antibiotic Footprint Calculator – that could make an important contribution in the fight against antimicrobial resistance (AMR), one of the world’s most significant emerging threats to public health.